Centessa Pharmaceuticals (NASDAQ:CNTA) Releases Quarterly Earnings Results

Centessa Pharmaceuticals (NASDAQ:CNTA) announced its earnings results on Tuesday. The company reported ($0.52) earnings per share (EPS) for the quarter, FiscalAI reports.

Centessa Pharmaceuticals Price Performance

CNTA traded down $0.07 on Wednesday, reaching $39.60. 634,037 shares of the company’s stock were exchanged, compared to its average volume of 2,335,837. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.57 and a quick ratio of 8.57. The stock’s fifty day moving average price is $33.17 and its 200-day moving average price is $27.94. Centessa Pharmaceuticals has a twelve month low of $10.95 and a twelve month high of $40.26. The stock has a market cap of $5.91 billion, a PE ratio of -26.94 and a beta of 1.13.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares of the company’s stock, valued at $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider directly owned 62,085 shares in the company, valued at $1,629,731.25. This trade represents a 65.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 309,112 shares of company stock worth $8,424,535 over the last ninety days. 7.09% of the stock is owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Foresite Capital Management VI LLC raised its stake in Centessa Pharmaceuticals by 4.8% during the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock worth $31,865,000 after purchasing an additional 60,640 shares during the period. Eagle Health Investments LP purchased a new position in Centessa Pharmaceuticals during the third quarter worth about $2,500,000. Royce & Associates LP purchased a new position in Centessa Pharmaceuticals during the third quarter worth about $5,999,000. Cinctive Capital Management LP purchased a new position in Centessa Pharmaceuticals during the third quarter worth about $2,246,000. Finally, Avoro Capital Advisors LLC raised its stake in shares of Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares during the period. 82.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Guggenheim lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Stephens lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Lifesci Capital lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Finally, Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target on the stock. in a research report on Monday, April 13th. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Hold” and an average target price of $40.70.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.